Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

NCT04513717 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT04513717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04513717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 21, 2021
Completion date
December 31, 2038
Enrollment
2,753 (actual)
Sites
602

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma, stage iii prostate cancer ajcc v8, stage iva prostate cancer ajcc v8